首页> 美国卫生研究院文献>Open Forum Infectious Diseases >Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients

【2h】

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients

机译：Bezlotoxumab在移植受者中预防复发性蛋白质艰难梭菌感染的有效性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Bezlotoxumab significantly reduces the incidence of recurrent Clostridioides difficile infection (CDI); however, limited data are available in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients.

机译：Bezlotoxumab显着降低了复发性梭氧化钛差异感染（CDI）的发生率;然而，有限的数据可用于固体器官移植（SOT）和造血细胞移植（HCT）接受者。

著录项

期刊名称 Open Forum Infectious Diseases
作者
Tanner M Johnson; Amanda H Howard; Matthew A Miller; Lorna L Allen; Misha Huang; Kyle C Molina; Valida Bajrovic;
展开▼
作者单位

展开▼
年(卷),期 2021(8),7
年度 2021
页码 ofab294
总页数 8
原文格式 PDF
正文语种
中图分类病毒传染病 ;
关键词

机译：Busotoxumab;CDI;

相似文献

外文文献
中文文献
专利

1. Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II [J] . Mark H Wilcox, Galia Rahav, Erik R Dubberke, Open Forum Infectious Diseases . 2019 ,第8期

机译：诊断方法对贝洛单抗预防难治性梭状芽胞杆菌复发的3期临床试验结果的影响：MODIFY I / II的事后分析
2. Outcomes of Norovirus diarrheal infections and Clostridioides difficile Clostridioides difficile infections in kidney transplant recipients: A single‐center retrospective study [J] . Rolak Stacey, Di Bartolomeo Sarah, Jorgenson Margaret R., Transplant infectious disease: an official journal of the Transplantation Society . 2019 ,第2期

机译：Norovirus腹泻感染和蛋白质酸纤维梭菌的结果腹部移植受者的艰难梭菌性感染：单中心回顾性研究
3. Management of Clostridioides Clostridioides (formerly Clostridium Clostridium ) difficile difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice [J] . Mullane Kathleen M., Dubberke Erik R., on behalf of the AST ID Community of Practice Clinical transplantation. . 2019 ,第9期

机译：蛋白质梭菌梭菌梭菌（以前的梭菌梭菌）艰难梭菌感染（CDI）在固体器官移植受者中：来自美国移植社区的实践社区的指导
4. Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisoeral transplantation: rejections and infections on 40 recipients during the early post-operative period. [C] . Zanfi C, Lauro A., Cescon M., International Small Bowel Transplant Symposium . 2009

机译：Daclizumab和Alemtuzumab作为成人肠道和多含量移植中的诱导剂：在术后期间的40名接受者中排斥和感染。
5. Use of Shotgun Metagenomic Sequencing to Determine How the Human Gut Microbiome and Antibiotic Resistome Influence the Risk of Recurrent Clostridioides difficile Infection [D] . ?Correa, Maria Alexandra 2020

机译：使用霰弹枪偏测元素测序以确定人体肠道微生物组和抗生素抵抗如何影响复发性梭氧化物差异感染的风险
6. Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II [O] . Mark H Wilcox, Galia Rahav, Erik R Dubberke, 2019

机译：诊断方法对贝洛单抗预防难治性梭状芽胞杆菌复发的3期临床试验结果的影响：MODIFY I / II的事后分析
7. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II [O] . Ellie J C Goldstein, Diane M Citron, Dale N Gerding, 2019

机译：Bezlotoxumab用于预防复发性梭氧化钛差异感染：来自随机期III试验的12个月观测数据，修改II

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients

摘要

著录项

相似文献

相关主题

期刊订阅